ACAM-CDIFF: Phase II started

sanofi-aventis' Sanofi Pasteur S.A. vaccines division began a 2-stage, double-blind, U.S. Phase II trial to evaluate ACAM-CDIFF in about 650 patients at risk for CDI. In the first stage, 450 patients...